Skip to search formSkip to main contentSkip to account menu

North American Brain Tumor Consortium

Known as: NABTC 
Dedicated to the development and conduct of innovative clinical trials that will ultimately result in a cure for patients with malignant brain tumors… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02).
2006 Background: The activity of targeted molecular therapy with single agents has been disappointing in GBM. Combination therapy… 
2016
2016
Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomas.
2062 Background: No effective treatment is available for recurrent meningiomas when surgical and radiation options are exhausted… 
2012
2012
Reply to J.W. Locasale et al
We appreciate the thoughtful comments by Locasale et al1 regarding the tumor biomarker analysis from our recent phase II clinical… 
2010
2010
Use of cytokines to predict on-target toxicity in patients with recurrent glioblastoma treated with aflibercept.
e12507 Background: On-target toxicity related to antiangiogenic therapy may be severe and limit treatment duration. Treatment… 
2010
2010
Abstract P5-01-12: Specific Tumor Component Spectrum as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
BACKGROUND: Monitoring individual tumor response to neoadjuvant chemotherapy could provide surrogate markers for oncologists to… 
2009
2009
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02).
2004 Background: Glioblastomas (GBM) frequently have EGFR amplification/mutations and inactivation of PTEN. Although single agent… 
2008
2008
How the North American Brain Tumor Consortium Shaped Clinical Research in Neuro–oncology
The North American Brain Tumor Consortium (NABTC) is one of three multi-institutional consortia initially funded by the National… 
2007
2007
Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with temozolomide (TMZ) in patients with malignant gliomas (NABTC 04–03)
2039 Background: Vorinostat (V) is an oral inhibitor of histone deacetylase. In preclinical studies it inhibits growth of… 
2007
2007
Joint NABTC + NCCTG prognostic factors analysis for high grade recurrent glioma
2075 Background: Multiple variables may impact endpoints used to assess therapeutic efficacy for patients with recurrent gliomas… 
Review
2005
Review
2005
Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors : Tissue Analysis fromNorth
Purpose:We investigated the molecular effect of the epidermal growth factor receptor (EGFR) inhibitors erlotinib and gefitinib in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)